Kamada Ltd. (KMDA)
NASDAQ: KMDA · Real-Time Price · USD
7.06
+0.10 (1.44%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Kamada Revenue
Kamada had revenue of $45.24M in the quarter ending March 31, 2026, with 2.78% growth. This brings the company's revenue in the last twelve months to $136.97M, up 9.75% year-over-year. In the year 2025, Kamada had annual revenue of $180.46M with 12.12% growth.
Revenue (ttm)
$136.97M
Revenue Growth
+9.75%
P/S Ratio
2.25
Revenue / Employee
$393,251
Employees
462
Market Cap
409.11M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 180.46M | 19.51M | 12.12% |
| Dec 31, 2024 | 160.95M | 18.43M | 12.93% |
| Dec 31, 2023 | 142.52M | 13.18M | 10.19% |
| Dec 31, 2022 | 129.34M | 25.70M | 24.79% |
| Dec 31, 2021 | 103.64M | -29.60M | -22.22% |
| Dec 31, 2020 | 133.25M | 6.06M | 4.76% |
| Dec 31, 2019 | 127.19M | 12.72M | 11.11% |
| Dec 31, 2018 | 114.47M | 11.64M | 11.32% |
| Dec 31, 2017 | 102.83M | 25.33M | 32.69% |
| Dec 31, 2016 | 77.49M | 7.59M | 10.85% |
| Dec 31, 2015 | 69.91M | -1.16M | -1.63% |
| Dec 31, 2014 | 71.07M | 442.00K | 0.63% |
| Dec 31, 2013 | 70.62M | -2.05M | -2.82% |
| Dec 31, 2012 | 72.68M | 13.19M | 22.18% |
| Dec 31, 2011 | 59.48M | 25.01M | 72.53% |
| Dec 31, 2010 | 34.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evotec SE | 859.03M |
| Tilray Brands | 858.28M |
| Emergent BioSolutions | 676.80M |
| Organogenesis Holdings | 514.70M |
| Ironwood Pharmaceuticals | 361.51M |
| Evolus | 301.79M |
| Akebia Therapeutics | 232.40M |
| Canopy Growth | 203.89M |
KMDA News
- 4 days ago - Kamada (KMDA) Secures $50M Plasma Supply Agreement - GuruFocus
- 5 days ago - Kamada enters $50M sales agreement to supply plasma to biopharmaceutical company - TheFly
- 5 days ago - Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies - GlobeNewsWire
- 11 days ago - Kamada (KMDA) Presents Promising Cytogam Study Results at Global Conference - GuruFocus
- 12 days ago - Kamada highlights Cytogam study results - TheFly
- 12 days ago - Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting - GlobeNewsWire
- 7 weeks ago - Kamada (KMDA) Receives FDA Nod for New Fluorescent Focus Inhibition Test - GuruFocus
- 7 weeks ago - Kamada Receives FDA Approval For In-House Rabies Virus Neutralization Testing Laboratory - Nasdaq